Single answer

Is Ascendis Pharma AS (ASND) a buy or sell?

4starter turns market data into one clear verdict you can act on.

Buy
$228.00
-6.99 (-2.97%)
Quote updated: 2026-02-25 21:00 UTC
Trend today
-2.97%
Down today
Volume vs avg
32.69%
1.33x over average
Target gap
25.66%
above current price
Signal updated
2026-02-25 16:30 UTC
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Add to watchlist

Create a free account to save tickers and track your signals.

Log in to turn on watchlist alerts.

Decision snapshot

Everything you need to act fast, in one glance.

4starter signal
Buy
80%
Score
Confidence score
Higher scores mean stronger signal alignment.

Powered by momentum, volatility, and trend inputs.

Analyst target gap
25.66%
$58.50 above current price

Consensus target $286.50.

Volume vs average
32.69%
over average

944,512 vs 711,810 average (1.33x normal).

What is the conclusion?

Right now our advanced algorithms say:

YES

$1 invested is now $1.44 or 43.94%

(In 16 weeks 2 days 20 hours 4 minutes and 55 seconds .)

Do analysts agree?

We compare consensus targets with today's price.

YES

Consensus target for Ascendis Pharma AS is $286.50, which is $58.50 (25.66%) above the current price today's price.

Low target: $250.00 | High target: $342.00

Latest analyst updates

Recent rating and price target changes for this stock.

Company snapshot

A quick overview of the business and its public profile.

Ascendis Pharma AS a biopharmaceutical company focuses on developing therapeutics for unmet medical needs The company offers SKYTROFA for treating patients with growth hormone deficiency GHD It also develops TransCon Growth Hormone hGH for pediatric GHD in Japan TransCon hGH for adults with GHD TransCon parathyroid hormone for adult hypoparathyroidism and TransCon CNP for pediatric achondroplasia In addition the company develops TransCon toll like receptors 78 agonist for intratumoral delivery and TransCon IL2 ssg for systemic delivery The company was incorporated in 2006 and is headquartered in Hellerup Denmark

Website: https://ascendispharma.com

Rates and inflation backdrop

US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.

Inflation sensitivity

Debt ratio: 0.67. Cash flow to debt ratio: 0.06. Net profit margin: -31.72%. Inflation risk score: high (1.00/1).

Dividend history check

We cannot find any recorded dividends paid in our systems.

Trading liquidity

Yes, the average daily trading liquidity for Ascendis Pharma AS is $135.9M. You should therefore be able to get in and out of your positions relatively fast.

10-year return check

On Ascendis Pharma AS, 2016-02-26 had a stock price of $17.91. If you invested back then, your return now would be a profit of $210.09 per share or 1,173.03%.

Why this answer

We combine price momentum, volatility, and trend signals to simplify the decision to one word.

1

Signal engine scans price, trend, and momentum indicators.

2

Targets and sentiment are checked against the live quote.

3

We keep the output simple: buy, sell, or hold.

Analyst consensus

How Wall Street targets compare to today's price.

$286.50
$58.50 (25.66%) above the current price
Range: $250.00 - $342.00

FAQ

Today's 4starter signal is Buy. That means the current data favors upside over downside.

Quotes and targets refresh throughout the trading day, with the latest timestamp shown on the page.

It blends momentum, trend, and volatility indicators into a single decision-oriented verdict.